NCT04186845 2025-09-22
Imaging Study to Investigate Safety and Diagnostic Performance of 18F rhPSMA 7.3 PET Ligand in Suspected Prostate Cancer Recurrence
Blue Earth Diagnostics
Phase 3 Completed
Clinical Trials
4 trialsNCT04186819 2025-02-26
Imaging Study to Investigate the Safety and Diagnostic Performance of rhPSMA 7.3 (18F) in Newly Diagnosed Prostate Cancer.
Blue Earth Diagnostics
Phase 3 Completed
NCT02981368 2021-08-09
OSPREY
Progenics Pharmaceuticals, Inc.
Phase 2/3 Completed
NCT03185182 2019-06-21
RCCSCAN
Region Skane
Phase 2 Terminated